These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21798780)

  • 1. Adherence to treatment in multiple sclerosis.
    Santolaya Perrín R; Fernández-Pacheco García Valdecasas M; Arteche Eguizabal L; Gema Pérez Pérez I; Muñoz Muñoz N; Ibarra Barrueta O; Callejón Callejón G
    Farm Hosp; 2012; 36(3):124-9. PubMed ID: 21798780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy adherence to immunomodulator treatment in patients with multiple sclerosis].
    López-Méndez P; Río J; Pérez-Ricart A; Tintoré M; Sastre-Garriga J; Cardona-Pascual I; Gómez-Domingo MR; Montalban X
    Rev Neurol; 2013 Jan; 56(1):8-12. PubMed ID: 23250676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
    Kleinman NL; Beren IA; Rajagopalan K; Brook RA
    J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
    Arroyo E; Grau C; Ramo-Tello C; Parra J; Sánchez-Soliño O;
    Eur Neurol; 2011; 65(2):59-67. PubMed ID: 21212677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence of adolescents to multiple sclerosis disease-modifying therapy.
    Thannhauser JE; Mah JK; Metz LM
    Pediatr Neurol; 2009 Aug; 41(2):119-23. PubMed ID: 19589460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
    Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.
    Oleen-Burkey MA; Dor A; Castelli-Haley J; Lage MJ
    J Med Econ; 2011; 14(6):739-47. PubMed ID: 21913796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.
    Kinkel RP; Dontchev M; Kollman C; Skaramagas TT; O'Connor PW; Simon JH;
    Arch Neurol; 2012 Feb; 69(2):183-90. PubMed ID: 21987393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].
    Arroyo E; Grau C; Ramo C; Parra J; Sánchez-Soliño O;
    Neurologia; 2010 Sep; 25(7):435-42. PubMed ID: 20964990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL;
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis.
    Patten SB; Williams JV; Metz LM
    Mult Scler; 2008 Apr; 14(3):406-11. PubMed ID: 17986504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
    McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA;
    Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.